NCT07339254

Brief Summary

This study evaluates patient satisfaction with receiving intravenous (IV) and/or subcutaneous (SC) immunotherapy and to assess patient preference for IV immunotherapy administration versus SC immunotherapy administration either at the hospital or at home.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
22mo left

Started Mar 2026

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress8%
Mar 2026Mar 2028

First Submitted

Initial submission to the registry

December 23, 2025

Completed
22 days until next milestone

First Posted

Study publicly available on registry

January 14, 2026

Completed
2 months until next milestone

Study Start

First participant enrolled

March 12, 2026

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 12, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

March 12, 2028

Last Updated

March 16, 2026

Status Verified

March 1, 2026

Enrollment Period

1 year

First QC Date

December 23, 2025

Last Update Submit

March 13, 2026

Conditions

Lung Non-Small Cell Carcinoma

Outcome Measures

Primary Outcomes (2)

  • Strength of patient perception of Intravenous (IV) Immune Checkpoint Inhibitor (ICI) therapy

    Outcome data will be collected using a questionnaire per study protocol. A Likert scale rating system of Strongly Disagree, Disagree, Neutral, Agree, Strongly Agree will be used. Summaries of data will be descriptive and standard statistical methods (median) will be used to present the results. Pearson's chi-square test, the Mantel-Haenszel test (or corresponding exact tests, if resulting expected numbers are small) will be used; the resulting p-value will be used as an indication of strength of an observed association.

    At Baseline through study completion, up to 1 year.

  • Patient interest in home SC ICI administration vs. IV ICI administration at the infusion center

    Outcome data will be collected using a questionnaire per study protocol. Results will be summarized with point estimates and confidence intervals; p-values, when calculated, will be used to indicate the strength of an observed association (not just the magnitude).

    At Baseline through study completion, up to 1 year.

Secondary Outcomes (6)

  • Strength of patient perception of Subcutaneous (SC) Immune Checkpoint Inhibitor (ICI) therapy.

    At Baseline through study completion, up to 1 year.

  • Strength of patient interest in home IV ICI administration vs. SC ICI administration at the infusion center.

    At Baseline through study completion, up to 1 year.

  • Transportation and social barriers to obtaining Intravenous (IV) Immune Checkpoint Inhibitor (ICI) therapy.

    At Baseline through study completion, up to 1 year.

  • Quality of life while on Immune Checkpoint Inhibitor (ICI) therapy

    At Baseline through study completion, up to 1 year.

  • Duration of ICI therapy

    Through study completion, up to 1 year.

  • +1 more secondary outcomes

Study Arms (1)

Observational

Patients complete surveys on study.

Other: Non-Interventional Study

Interventions

Non-Interventional StudyOTHER

Non-interventional study

Also known as: Non-Interventional Observational Study, Noninterventional (Observational) Study
Observational

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with non-small cell lung cancer, currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, or Pembrolizumab.

You may qualify if:

  • \* Age ≥ 18 years.
  • \* Patients must have histopathologically/cytologically confirmed non-small cell lung cancer, currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab (i.e. the patient has already received at least one cycle of therapy)
  • \* Previous chemotherapy/radiotherapy/targeted/immunotherapy is allowed at any prior timepoint.
  • \* Ability to understand and the willingness to sign a written informed consent or presence of a surrogate decision maker who can give consent.

You may not qualify if:

  • \* Patients is unable to consent for themselves
  • \* Patient has not yet completed the 1st cycle of ICI-based therapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Los Angeles General Medical Center

Los Angeles, California, 90033, United States

RECRUITING

USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States

RECRUITING

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Robert Hsu

    University of Southern California

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 23, 2025

First Posted

January 14, 2026

Study Start

March 12, 2026

Primary Completion (Estimated)

March 12, 2027

Study Completion (Estimated)

March 12, 2028

Last Updated

March 16, 2026

Record last verified: 2026-03

Locations

US(2)